摘要
Background Exercise rehabilitation and self-management intervention therapy models have been confirmed beneficial for patients with acute myocardial infarction,but the effect remains unclear for heart failure(HF)case.Methods This study included 72 patients with HF admitted to the Guangdong Provincial People.s Hospital from 2017 to 2020.According to whether the patients were admitted to the hospital before the establishment of the Heart Failure Center(in 2019)or not,patients were assigned to either the control group(n=31)or the combined treatment group(n=41).The patient.s treatment process data were mainly collected through the inpatient system.Endpoints and in-hospital events were recorded.Multivariate Poisson regression was used to evaluate the difference between two groups.Results Baseline data,including gender,age,height,weight,systolic blood pressure,diastolic blood pressure,cardiac function classification,and medication prescription,demonstrated no significant difference between two groups.During hospitalization,there were no deaths in both groups.Analysis showed that the median duration of edema symptoms in the combined treatment group was significantly shorter than that in the control group[3(2-5)days vs.5(4-8)days,respectively,RR:0.73,95%CI:0.62-0.87,P<0.001].At the same time,the median hospital stay of patients in the combined treatment group was also significantly shorter than that in the control group[7(5-8)days vs.9(7-13)days,respectively,RR:0.57,95%CI:0.45-0.72,P<0.001].Conclusions Exercise rehabilitation combined with self-management intervention in patients with HF may accelerate the regression of patients.edema and shorten the length of hospital stay.
基金
supported by Guangdong Medical Science and Technology Research Fund Project(No.B2020204)
Guangdong Provincial People’s Medical Climbing Plan(Nursing Research Project)(No.DFJH2020011)
Department of Science and Technology of Guangdong Province Project(No.2017B020247060)
Beijing Li-Sheng Cardiovascular Health Foundation Pilot Fund Project(No.LHJJ201612127)
Guangdong Provincial Clinical Drug Research Fund(No.2019ZX01)。
